| Dr Joseph Minter Payne, | |
|
2221 S 17th St, Wilmington, NC 28401-7542 | |
| (910) 662-7720 | |
| (910) 815-0840 |
| Full Name | Dr Joseph Minter Payne |
|---|---|
| Gender | Male |
| Speciality | Colorectal Surgery (proctology) |
| Experience | 40 Years |
| Location | 2221 S 17th St, Wilmington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205854452 | NPI | - | NPPES |
| 020030293 | Other | NC | RAILROAD MEDICARE |
| 66291 | Other | NC | BCBS NC |
| 8966291 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 29494 (North Carolina) | Secondary |
| 208C00000X | Colon & Rectal Surgery | 29494 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New Hanover Regional Medical Center | Wilmington, NC | Hospital |
| Pender Memorial Hospital | Burgaw, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novant Health Medical Group Coastal Region Llc | 2860809936 | 412 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Entity Name | Carolinaeast Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104066794 PECOS PAC ID: 0143378117 Enrollment ID: O20090430000303 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Entity Name | Dhp Of North Carolina Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780949032 PECOS PAC ID: 1153570783 Enrollment ID: O20120925000775 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Entity Name | New Hanover Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952705519 PECOS PAC ID: 0143110460 Enrollment ID: O20141215000576 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Entity Name | Novant Health New Hanover Regional Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750978839 PECOS PAC ID: 7113330168 Enrollment ID: O20210112000621 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Entity Name | Novant Health Medical Group Coastal Region Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649865791 PECOS PAC ID: 2860809936 Enrollment ID: O20210408000285 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Minter Payne, Po Box 936857, Atlanta, GA 31193-6857 Ph: (910) 662-7720 | Dr Joseph Minter Payne, 2221 S 17th St, Wilmington, NC 28401-7542 Ph: (910) 662-7720 |
News Archive
President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.
Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova's NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.
A new study released today shows that rising obesity rates will continue to be an increasing burden on the health care system over the next decade. The report, titled, "The Future Cost of Obesity: National and State Estimates of the Impact of Obesity on Direct Health Care Expenses," is the first to estimate obesity prevalence and costs at the state and national level 10 years from now.
Alere Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has made additional open market purchases of 2,091,764 shares of Axis-Shield stock, bringing its total current ownership position to 3,204,995 shares, or approximately 6.4%, of Axis-Shield's issued and outstanding ordinary share capital.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).
› Verified 9 days ago